BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ariceta G, Dixon BP, Kim SH, Kapur G, Mauch T, Ortiz S, Vallee M, Denker AE, Kang HG, Greenbaum LA; 312 Study Group. The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. Kidney Int 2021;100:225-37. [PMID: 33307104 DOI: 10.1016/j.kint.2020.10.046] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Raina R, Vijayvargiya N, Khooblall A, Melachuri M, Deshpande S, Sharma D, Mathur K, Arora M, Sethi SK, Sandhu S. Pediatric Atypical Hemolytic Uremic Syndrome Advances. Cells 2021;10:3580. [PMID: 34944087 DOI: 10.3390/cells10123580] [Reference Citation Analysis]
2 Ehren R, Habbig S. Real-world data of six patients with atypical hemolytic uremic syndrome switched to ravulizumab. Pediatr Nephrol 2021;36:3281-2. [PMID: 34274988 DOI: 10.1007/s00467-021-05203-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Devarajan P, Chertow GM, Susztak K, Levin A, Agarwal R, Stenvinkel P, Chapman AB, Warady BA. Emerging Role of Clinical Genetics in CKD. Kidney Medicine 2022. [DOI: 10.1016/j.xkme.2022.100435] [Reference Citation Analysis]
4 Sangeetha G, Jayaraj J, Ganesan S, Puttagunta S. Atypical haemolytic uraemic syndrome: a case of rare genetic mutation. BMJ Case Rep 2021;14:e244190. [PMID: 34330731 DOI: 10.1136/bcr-2021-244190] [Reference Citation Analysis]
5 Levy AR, Chen P, Johnston K, Wang Y, Popoff E, Tomazos I. Quantifying the economic effects of ravulizumab versus eculizumab treatment in patients with atypical hemolytic uremic syndrome. J Med Econ 2022;:1-16. [PMID: 35020547 DOI: 10.1080/13696998.2022.2027706] [Reference Citation Analysis]
6 Syed YY. Ravulizumab: A Review in Atypical Haemolytic Uraemic Syndrome. Drugs 2021;81:587-94. [PMID: 33738756 DOI: 10.1007/s40265-021-01481-6] [Reference Citation Analysis]
7 Zununi Vahed S, Rahbar Saadat Y, Ardalan M. Thrombotic microangiopathy during pregnancy. Microvasc Res 2021;138:104226. [PMID: 34252400 DOI: 10.1016/j.mvr.2021.104226] [Reference Citation Analysis]
8 Brodsky RA. Eculizumab and aHUS: to stop or not. Blood 2021;137:2419-20. [PMID: 33956069 DOI: 10.1182/blood.2020010234] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Dixon BP, Sabus A. Ravulizumab 100 mg/mL formulation reduces infusion time and frequency, improving the patient and caregiver experience in the treatment of atypical haemolytic uraemic syndrome. J Clin Pharm Ther 2022. [PMID: 35304755 DOI: 10.1111/jcpt.13642] [Reference Citation Analysis]
10 Palma LMP, Vaisbich-Guimarães MH, Sridharan M, Tran CL, Sethi S. Thrombotic microangiopathy in children. Pediatr Nephrol 2022. [PMID: 35041041 DOI: 10.1007/s00467-021-05370-8] [Reference Citation Analysis]
11 Yoo JJ, Chonat S. Evaluating ravulizumab for the treatment of children and adolescents with paroxysmal nocturnal hemoglobinuria. Expert Rev Hematol 2022. [PMID: 35502699 DOI: 10.1080/17474086.2022.2073215] [Reference Citation Analysis]